{"id":379555,"date":"2020-11-12T08:03:38","date_gmt":"2020-11-12T13:03:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379555"},"modified":"2020-11-12T08:03:38","modified_gmt":"2020-11-12T13:03:38","slug":"adaptimmune-to-host-virtual-investor-day-on-friday-november-20th","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/","title":{"rendered":"Adaptimmune to Host Virtual Investor Day on Friday, November 20th"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov.  12, 2020  (GLOBE NEWSWIRE) &#8212; Adaptimmune\u00a0Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will\u00a0host\u00a0a virtual\u00a0Investor Day\u00a0on November\u00a020, 2020\u00a0at 8AM EST\/ 1PM GMT.\u00a0A\u00a0link to register is available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Edcd5k31K2eoItnFcwTngkbC_LCQd5-hjOh0SdZ99IvQTykES0IV3aJfYFSmbd5wArNlqOoEdCC95gaWSpU_nTmrOfqdhnj_duoZObrp07wKPW8BOlLuPZt1FoH7FhFJEFATmrBbQRA7xaE9122pq-KlUv-M3oj9g-QH9ktzSydZmrz0yNlol0BFrFUYA1YO4vtP8WbK0ZDSnKHufeF1F55pLzIFJeFohiMfJE63xnmK8Ymj2GMOC8yhveBYgTeP0SpGhK7rJMaDIDX26ruE1wiXioBd7jjhS3fd8QxVCuTbxHOwdrf77wpm9kZcqPa9\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">HERE<\/a> and further details are on the Investor Relations tab of the\u00a0Adaptimmune\u00a0website.<\/p>\n<p align=\"left\">The Company plans to showcase the market potential for its SPEAR T-cell portfolio as well as provide details about its early stage pipeline with multiple cell therapies beyond its current autologous TCR T-cell products. Presentations will be given by\u00a0Adaptimmune\u2019s\u00a0Senior Leadership Team in addition to Dr. Dejka Araujo from the Department of Sarcoma Medical Oncology, Division of Cancer Medicine of the MD Anderson Cancer Center.<\/p>\n<p align=\"left\">\n        <strong>About\u00a0Adaptimmune<\/strong>\u00a0<br \/>Adaptimmune\u00a0is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company\u2019s unique SPEAR<sup>\u00ae<\/sup>\u00a0(Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.\u00a0<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong>\u00a0<br \/>This release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and\u00a0commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.\u00a0<\/p>\n<p align=\"left\">\n        <strong>Media Relations:<\/strong>\n      <\/p>\n<p align=\"left\">S\u00e9bastien Desprez \u2014 VP, Communications and Investor Relations<br \/>T: +44 1235 430 583<br \/>M: +44 7718 453 176<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vKS5CjnSQI8QbTxHW5lShd_bU4bXsc6uqtjaDSHSVQ4Mcv3DnQo2nCMvakrO4IT8OZmPuPKvdBs8E1sTgSDAlNu84PQ3B49t-BFglkvxQCmutinUmxTKcRn1HEirs7qt\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Sebastien.Desprez@adaptimmune.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Investor Relations:<\/strong>\n      <\/p>\n<p align=\"left\">Juli P. Miller, Ph.D. \u2014 Senior Director, Investor Relations<br \/>T: +1 215 825 9310<br \/>M: +1 215 460 8920<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DuTYVDllMYONn_rZ-Z0UZwLfwfsQdMLf6P5uy2Z6nCRBOWqR4MhZCJ8JUNcluYPexsHwnji9oR6_ekLkdVd0fTdmDATn_c4SdzeEUIxFbokEkhfeKPkkUE9v7o-b4DQg\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Juli.Miller@adaptimmune.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Adaptimmune\u00a0Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will\u00a0host\u00a0a virtual\u00a0Investor Day\u00a0on November\u00a020, 2020\u00a0at 8AM EST\/ 1PM GMT.\u00a0A\u00a0link to register is available HERE and further details are on the Investor Relations tab of the\u00a0Adaptimmune\u00a0website. The Company plans to showcase the market potential for its SPEAR T-cell portfolio as well as provide details about its early stage pipeline with multiple cell therapies beyond its current autologous TCR T-cell products. Presentations will be given by\u00a0Adaptimmune\u2019s\u00a0Senior Leadership Team in addition to Dr. Dejka Araujo from the Department of Sarcoma Medical Oncology, Division of Cancer Medicine of the MD Anderson Cancer Center. About\u00a0Adaptimmune\u00a0Adaptimmune\u00a0is a clinical-stage biopharmaceutical company focused on the development &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Adaptimmune to Host Virtual Investor Day on Friday, November 20th&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379555","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adaptimmune to Host Virtual Investor Day on Friday, November 20th - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adaptimmune to Host Virtual Investor Day on Friday, November 20th - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Adaptimmune\u00a0Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will\u00a0host\u00a0a virtual\u00a0Investor Day\u00a0on November\u00a020, 2020\u00a0at 8AM EST\/ 1PM GMT.\u00a0A\u00a0link to register is available HERE and further details are on the Investor Relations tab of the\u00a0Adaptimmune\u00a0website. The Company plans to showcase the market potential for its SPEAR T-cell portfolio as well as provide details about its early stage pipeline with multiple cell therapies beyond its current autologous TCR T-cell products. Presentations will be given by\u00a0Adaptimmune\u2019s\u00a0Senior Leadership Team in addition to Dr. Dejka Araujo from the Department of Sarcoma Medical Oncology, Division of Cancer Medicine of the MD Anderson Cancer Center. About\u00a0Adaptimmune\u00a0Adaptimmune\u00a0is a clinical-stage biopharmaceutical company focused on the development &hellip; Continue reading &quot;Adaptimmune to Host Virtual Investor Day on Friday, November 20th&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T13:03:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adaptimmune to Host Virtual Investor Day on Friday, November 20th\",\"datePublished\":\"2020-11-12T13:03:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/\"},\"wordCount\":381,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/\",\"name\":\"Adaptimmune to Host Virtual Investor Day on Friday, November 20th - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM=\",\"datePublished\":\"2020-11-12T13:03:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adaptimmune to Host Virtual Investor Day on Friday, November 20th\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adaptimmune to Host Virtual Investor Day on Friday, November 20th - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/","og_locale":"en_US","og_type":"article","og_title":"Adaptimmune to Host Virtual Investor Day on Friday, November 20th - Market Newsdesk","og_description":"PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Adaptimmune\u00a0Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will\u00a0host\u00a0a virtual\u00a0Investor Day\u00a0on November\u00a020, 2020\u00a0at 8AM EST\/ 1PM GMT.\u00a0A\u00a0link to register is available HERE and further details are on the Investor Relations tab of the\u00a0Adaptimmune\u00a0website. The Company plans to showcase the market potential for its SPEAR T-cell portfolio as well as provide details about its early stage pipeline with multiple cell therapies beyond its current autologous TCR T-cell products. Presentations will be given by\u00a0Adaptimmune\u2019s\u00a0Senior Leadership Team in addition to Dr. Dejka Araujo from the Department of Sarcoma Medical Oncology, Division of Cancer Medicine of the MD Anderson Cancer Center. About\u00a0Adaptimmune\u00a0Adaptimmune\u00a0is a clinical-stage biopharmaceutical company focused on the development &hellip; Continue reading \"Adaptimmune to Host Virtual Investor Day on Friday, November 20th\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T13:03:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adaptimmune to Host Virtual Investor Day on Friday, November 20th","datePublished":"2020-11-12T13:03:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/"},"wordCount":381,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/","name":"Adaptimmune to Host Virtual Investor Day on Friday, November 20th - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM=","datePublished":"2020-11-12T13:03:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NDkwOCMzODI0MDA0IzIwMTg3NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adaptimmune to Host Virtual Investor Day on Friday, November 20th"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379555"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379555\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}